Perrigo (PRGO) Interest Expenses (2013 - 2026)
Perrigo's (PRGO) quarterly Interest Expenses came in at $20.8 million in Q1 2026, up 5.58% year-on-year from $19.7 million in Q1 2025, and down 88.08% on a QoQ basis from $174.5 million in Q4 2025.
Perrigo (PRGO) Interest Expenses (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Interest Expenses data on file, last reported at $20.8 million in Q1 2026.
- On a quarterly basis, Interest Expenses rose 5.58% year-over-year to $20.8 million in Q1 2026; TTM through Mar 2026 was $20.8 million, a 5.58% increase from a year earlier, with the FY2025 full-year figure at $618.5 million, down 56.63% from the prior year.
- Interest Expenses for Q1 2026 stood at $20.8 million, down from $174.5 million in the prior quarter.
- Over the last five years, Interest Expenses for PRGO reached as high as $249.9 million in Q4 2023 and fell as low as $6.1 million in Q4 2024.
- Historically, Interest Expenses has averaged $116.2 million across 5 years, with a median of $30.2 million in 2025.
- Across the five-year window, Interest Expenses sank 97.56% in 2024 and surged 2760.66% in 2025, its largest moves.
- Year by year, Interest Expenses stood at $186.4 million in 2022, then surged by 34.07% to $249.9 million in 2023, then sank by 97.56% to $6.1 million in 2024, then jumped by 2760.66% to $174.5 million in 2025, then tumbled by 88.08% to $20.8 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $20.8 million in Q1 2026, $174.5 million in Q4 2025, and $23.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 62.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 944.51 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 1.77 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.21 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 590.20 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.04 Bn | 325.50 Mn | 20.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 20.80 Mn |
| Mar 28, 2026 | 20.80 Mn |
| Dec 31, 2025 | 174.50 Mn |
| Dec 31, 2025 | 174.50 Mn |
| Sep 27, 2025 | 23.40 Mn |
| Sep 27, 2025 | 23.40 Mn |
| Jun 28, 2025 | 30.20 Mn |
| Jun 28, 2025 | 30.20 Mn |
| Mar 29, 2025 | 19.70 Mn |
| Mar 29, 2025 | 19.70 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Dec 31, 2024 | 6.10 Mn |
| Sep 28, 2024 | 223.20 Mn |
| Sep 28, 2024 | 223.20 Mn |
| Jun 29, 2024 | 228.50 Mn |
| Jun 29, 2024 | 228.50 Mn |
| Mar 30, 2024 | 22.60 Mn |
| Mar 30, 2024 | 22.60 Mn |
| Dec 31, 2023 | 249.90 Mn |
| Dec 31, 2023 | 249.90 Mn |